FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250651683> ?p ?o ?g. }

• W4250651683 endingPage "608" @default.
• W4250651683 startingPage "608" @default.
• W4250651683 abstract "We thank Fazili et al. for their interest in our article. The development of antibodies to hepatitis B e antigen (anti-HBe) and hepatitis B surface antigen (anti-HBs) were lower in the lamivudine-treated group relative to placebo, although these did not reach statistical significance. We concur with Fazili et al. that it is an important observation, and it seems plausible that interruption of the protective host immune response may be a consequence of pharmacologic therapy. Because virus-specific antibody-producing B cells are enriched early after acute viral infection,1 the host immune system needs to be exposed to viral antigen during the early phase in order to induce production of neutralizing antibodies. Therefore, giving lamivudine early may inhibit the production of neutralizing antibodies to some extent.2 A previous study also reported that after the use of lamivudine in treating acute viral hepatitis B, 18.18% of patients lost serum HBsAg but did not develop anti-HBs during treatment and follow-up.3 Nevertheless, it has also been reported that anti-HBs did not develop in 10% of untreated patients with acute hepatitis B.4 As rightly mentioned, only a long-term follow-up of such patients would help us know the risk of reactivation of hepatitis B virus (HBV) in patients treated with antiviral therapy. We do believe however that treatment of patients with severe acute hepatitis B with lamivudine is not harmful. Lamivudine or other more potent antivirals may be useful in a small subset of patients with acute hepatitis B who have more severe disease at presentation and high HBV DNA. Although there are no studies defining the patients with more severe disease, we suggest that such patients might include individuals with fulminant acute hepatitis B,5 or individuals who fulfill any 2 of the following criteria:3, 6 (1) hepatic encephalopathy; (2) serum bilirubin ≥ 10.0 mg/dL; and (3) international normalized ratio (INR) ≥ 1.6, especially if it is increasing. Because patients belonging to the above categories would often need liver transplantation, it would be best to achieve, through use of potent antiviral drugs, HBV DNA levels which are undetectable or as low as possible at the time of liver transplantation, as measured with current real-time polymerase chain reaction methods. Whether such a therapeutic approach may translate into spontaneous recovery in a proportion of patients awaiting transplantation can only be predicted by the use of antiviral drugs in proper RCTs including such a group of patients. Manoj Kumar M.D., D.M.*, Shiv K. Sarin M.D., D.M.*, Barjesh C. Sharma M.D., D.M.*, * Department of Gastroenterology, G. B. Pant Hospital, New Delhi, India." @default.
• W4250651683 created "2022-05-12" @default.
• W4250651683 creator A5010779172 @default.
• W4250651683 creator A5026415059 @default.
• W4250651683 creator A5041891746 @default.
• W4250651683 date "2007-01-01" @default.
• W4250651683 modified "2023-09-28" @default.
• W4250651683 title "Reply:" @default.
• W4250651683 cites W2026300366 @default.
• W4250651683 cites W2029691647 @default.
• W4250651683 cites W2134810425 @default.
• W4250651683 cites W2159101750 @default.
• W4250651683 doi "https://doi.org/10.1002/hep.21882" @default.
• W4250651683 hasPublicationYear "2007" @default.
• W4250651683 type Work @default.
• W4250651683 citedByCount "1" @default.
• W4250651683 countsByYear W42506516832013 @default.
• W4250651683 crossrefType "journal-article" @default.
• W4250651683 hasAuthorship W4250651683A5010779172 @default.
• W4250651683 hasAuthorship W4250651683A5026415059 @default.
• W4250651683 hasAuthorship W4250651683A5041891746 @default.
• W4250651683 hasBestOaLocation W42506516831 @default.
• W4250651683 hasConcept C147483822 @default.
• W4250651683 hasConcept C159047783 @default.
• W4250651683 hasConcept C159654299 @default.
• W4250651683 hasConcept C203014093 @default.
• W4250651683 hasConcept C2522874641 @default.
• W4250651683 hasConcept C2777382497 @default.
• W4250651683 hasConcept C2777410769 @default.
• W4250651683 hasConcept C2777869810 @default.
• W4250651683 hasConcept C2780593183 @default.
• W4250651683 hasConcept C71924100 @default.
• W4250651683 hasConcept C8891405 @default.
• W4250651683 hasConceptScore W4250651683C147483822 @default.
• W4250651683 hasConceptScore W4250651683C159047783 @default.
• W4250651683 hasConceptScore W4250651683C159654299 @default.
• W4250651683 hasConceptScore W4250651683C203014093 @default.
• W4250651683 hasConceptScore W4250651683C2522874641 @default.
• W4250651683 hasConceptScore W4250651683C2777382497 @default.
• W4250651683 hasConceptScore W4250651683C2777410769 @default.
• W4250651683 hasConceptScore W4250651683C2777869810 @default.
• W4250651683 hasConceptScore W4250651683C2780593183 @default.
• W4250651683 hasConceptScore W4250651683C71924100 @default.
• W4250651683 hasConceptScore W4250651683C8891405 @default.
• W4250651683 hasIssue "2" @default.
• W4250651683 hasLocation W42506516831 @default.
• W4250651683 hasOpenAccess W4250651683 @default.
• W4250651683 hasPrimaryLocation W42506516831 @default.
• W4250651683 hasRelatedWork W1506797373 @default.
• W4250651683 hasRelatedWork W1556816728 @default.
• W4250651683 hasRelatedWork W2028972195 @default.
• W4250651683 hasRelatedWork W2164269826 @default.
• W4250651683 hasRelatedWork W2169117603 @default.
• W4250651683 hasRelatedWork W2343415936 @default.
• W4250651683 hasRelatedWork W2382375426 @default.
• W4250651683 hasRelatedWork W2780574522 @default.
• W4250651683 hasRelatedWork W3031056812 @default.
• W4250651683 hasRelatedWork W4213348049 @default.
• W4250651683 hasVolume "46" @default.
• W4250651683 isParatext "false" @default.
• W4250651683 isRetracted "false" @default.
• W4250651683 workType "article" @default.